NY-PHILIP-MORRIS-INTL
19.1.2021 10:54:46 CET | Business Wire | Press release
Charles Bendotti, Senior Vice President, People & Culture at Philip Morris International Inc. (PMI) (NYSE:PM), has today been recognized for his unwavering support for LGBTQ+ inclusion in the workplace, included on INvolve and Yahoo Finance’s OUTstanding 50 Ally Executives List 2020. The designation places Bendotti among a select group of business leaders and allies of LGBTQ+ inclusion recognized for driving cultural change within the workplace to create more inclusive environments across the world. Nikki Symmons, Content Planner, Global Communications at PMI, has also been named on the OUTstanding LGBT+ Future Leader List 2020 in recognition of her achievements in furthering LGBTQ+ inclusion both within PMI and beyond.
“I’ve been fortunate to have lived and led in many countries throughout my career, working with people from a variety of backgrounds and cultures who have taught me the value of inclusion and diversity first-hand,” said Bendotti. “I’m honored to be recognized as a global ally and included on the OUTstanding 50 Ally Executives List this year. As leaders it’s critical that everyone—without exception—feels valued, respected, and empowered to succeed.”
Bendotti’s recognition stems from his efforts in championing inclusion and diversity (I&D) within PMI and beyond. He was instrumental in championing the appointment of the company’s first Chief Diversity Officer, Silke Muenster, in March 2020; a role that reports directly to the CEO. Additionally, he is actively involved in advancing LGBTQ+ inclusion within the organization as executive sponsor of PMI’s global employee resource group, STRIPES, which aims to create a safe space for learning, sharing, allyship, and support to members and allies of the LGBTQ+ community.
Suki Sandhu OBE, founder, and CEO of INvolve, the consultancy and global network championing diversity and inclusion in business, said: “I’m thrilled to be celebrating another amazing group of LGBT+ and Ally role models from across the globe who are championing inclusion and inspiring the next generation of talent. LGBT+ discrimination is still prevalent across the world, and role models are essential to change perceptions and show everyone that you can be successful in business while also being your authentic self at work.”
For inclusion on the OUTstanding 50 Ally Executives List 2020, nominees’ seniority and influence were taken into consideration and their impact on LGBTQ+ inclusion inside and outside the workplace, as well as business achievements. They must be a vocal ally, actively working to create an environment where LGBTQ+ people can comfortably bring their best professional selves to work.
OUTstanding’s judging panel consisted of Lord Browne, executive chairman, L1 Energy; Ashok Vaswani, global consumer and payments head, Barclays; Harriet Green, former chairman and CEO, IBM Asia Pacific; Dawn Airey, independent director, Grosvenor Estates GBI; Jim Fitterling, CEO of Dow Inc.; Suki Sandhu OBE, founder and CEO, INvolve and Audeliss; and Lianna Brinded, head of Yahoo Finance UK.
The full list of nominees can be viewed here . For more information on PMI’s I&D efforts, click here .
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Sept. 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .
About INvolve and OUTstanding
OUTstanding is part of INvolve, the consultancy and global network championing diversity and inclusion in business. Through the delivery of events, programs, thought leadership, and advisory services, INvolve helps firms drive cultural change and create inclusive workplaces where any individual can succeed. INvolve also publishes EMpower, HERoes, and OUTstanding role model lists annually, recognizing and celebrating business leaders and future leaders who are breaking down barriers at work and inspiring the next generation of diverse talent. For more information, please visit www.involvepeople.org
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
